Qilu Pharmaceutical is one of the leading vertically integrated pharmaceutical companies in China focusing on the development, manufacturing and marketing of active pharmaceutical ingredients (APIs) & finished formulations. Qilu currently has 12 subsidiaries, 10 manufacturing sites and over 23000 employees worldwide, 70% of whom are with bachelor’s degree or above. It ranks No.8 in Chinese pharmaceutical industry by sales revenue in 2019. Dedicated to offering more affordable medicines to the world and improving people's well-being, Qilu has exported its products to over 70 countries.
Qilu Pharmaceutical has always maintained an innovative development strategy guided by the market demand and is achieving its organic growth strategy utilizing a strong pool of 2000+ scientists spread across 5 R&D platforms based in the US (Seattle WA, Boston MA, San Francisco CA) and China (Shanghai, Jinan). To date, Qilu has launched 200+ products with 30+ products “First to launch” in China and 3 products “D181 launch” in US. The company has also a robust pipeline, including 200+ generic products, 20+ biosimilar products and 50+ innovative products.
Qilu Pharmaceutical has always committed itself to providing high-quality products to patients and the society. The company is the 1st Chinese company to obtain USFDA and EDQM approval for sterile APIs. Its finished formulations and APIs have been approved by USFDA, European Medicines Agency (EMA), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, PMDA of Japan and other national regulatory authorities.
Qilu Pharmaceutical has established a comprehensive domestic and overseas sales network, which covers North and South Americas, Europe, Asia, Australia, New Zealand, CIS (Commonwealth of Independent States) countries, South Africa and the Middle East. The valuable brand of the company has been well established with the quality products and good services.